Read Original Story

Hormone May Boost Aging, Failing Brains


3 Star

Hormone May Boost Aging, Failing Brains

Our Review Summary

When a single injection may cost $700, we don’t know why that information is not included in the story. Reuters did – up high in its story.  We also thought Reuters painted a far clearer picture of the limitations of the current research.


Why This Matters

Earlier studies have suggested that GHRH and IGF-1 play important roles in the cognitive decline associated with normal aging and in patients with Alzheimers disease.  Recent studies in otherwise healthy older adults have suggested that supplementation with GHRH may improve executive function.  This study provides a bit of additional evidence that GHRH may play a role in the treatment of cognitive decline in older adults.  But the story is far from clear and this work should be viewed as a preliminary step and not the end of the journey.  There isn’t a proven intervention for mild cognitive impairment.  So news stories about research in this field needs to be clear about the state of research.


Does the story adequately discuss the costs of the intervention?

Not Satisfactory

Cost was never mentioned – a significant oversight since, as Reuters Health reported, a single shot may cost $700.

Does the story adequately quantify the benefits of the treatment/test/product/procedure?

Not Satisfactory

We were puzzled by the lack of clarity of the benefits.  While benefits were not quantified, the impact of GHRH on IGF-1 was.  We think that the statement in the Reuters story: “It’s unclear how the test differences will translate into real life,” provided a clear statement on benefit

Does the story adequately explain/quantify the harms of the intervention?

Not Satisfactory

The story mentioned spiked insulin levels.  But it didn’t mention any of the side effects reported in the study:

“Adverse events primarily consisted of local skin
reactions (redness, itching, or stinging) and increased arthralgias.
Other adverse events reported, although less
frequently, included gastrointestinal upset, numbness or
tingling in the hands, weight gain, and fluid retention.
Although increased fluid retention can potentially precipitate
or exacerbate symptoms of congestive heart failure
and hypertension, coronary adverse events were not
observed in our study.”

Does the story seem to grasp the quality of the evidence?


The ending of the story included some evaluation of the evidence, including an independent perspective and this final sentence:

“The researchers said larger and longer trials are needed to assess the hormone’s therapeutic potential.”


Does the story commit disease-mongering?


No disease mongering at play here.

But, we were a bit troubled by the suggestion that people with mild cognitive impairment, “…don’t yet have Alzheimer’s disease…”  While MCI is a precursor, not all people with it go on to develop Alzheimer’s disease.


Does the story use independent sources and identify conflicts of interest?


One independent expert’s input was important at the end of the story.

Does the story compare the new approach with existing alternatives?

Not Satisfactory

There wasn’t the kind of clear context and background as provided in the Reuters story:

“…researchers have failed so far to come up wiht effective drugs to treat mild cognitive impairment, just as there is no known treatment to stave off the normal memory decline that comes with age.”

Does the story establish the availability of the treatment/test/product/procedure?

Not Satisfactory

There could have been a line or two about how GHRH is used now in medicine and whether there is much off-label use of the injections.

Does the story establish the true novelty of the approach?


The story at least established that the same team had done prior work with GHRH.

Does the story appear to rely solely or largely on a news release?


There’s no sign that the story relied on a news release.

Total Score: 5 of 10 Satisfactory


We Welcome Comments. But please note: We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, profanity or any from anyone who doesn't list what appears to be an actual email address. We will also end any thread of repetitive comments. We don't give medical advice so we won't respond to questions asking for it. Please see more on our comments policy.